Stabilized formulations containing Anti-angptl3 antibodies

MYPI2026002522A0Undetermined Publication Date: 2020-11-24REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2026002522
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-05-24
Filing Date
2020-05-24
Publication Date
2020-11-24
Patent Text Reader

Abstract

The present invention provides stable pharmaceutical formulations comprising a human antibody that specifically binds to human angiopoietin-like protein 3 (ANGPTL3). The formulations may contain, in addition to an anti-ANGPTL3 antibody, a buffer; an organic cosolvent; at least one viscosity modifier, and optionally at least one amino acid. The pharmaceutical formulations of the present invention can be administered via intravenous infusion or subcutaneously and exhibit a substantial degree of antibody stability after storage for several months.
Need to check novelty before this filing date? Find Prior Art